Hormonal alterations in heart failure: Anabolic impairment in chronic heart failure - Diagnostic, prognostic and therapeutic issues

Michele Arcopinto, Antonio Cittadini

Research output: Contribution to journalArticle

Abstract

Chronic heart failure represents a leading cause of mortality and health care expenditure in developed countries. In the last 20 years, medical therapy of heart failure has dramatically changed thanks to the introduction of agents able to significantly reduce the neurohormonal hyperactivation that underpins the syndrome, and to the growing opportunities of electrical therapies. Although major advances in terms of improved survival and quality of life have been achieved, the reduction in the burden of heart failure is still the primary goal of cardiovascular societies. In the last decades, other research lines have also grown to complement the neurohormonal paradigm. It is increasingly evident that several hormonal systems are down-regulated or impaired in patients with heart failure, including growth and thyroid hormones, androgens and insulin. These abnormalities could be considered interrelated and linked, in turn, to the neurohormonal and cytokine hyperactivation. Since most of these alterations provide prognostic information, these new lines of evidence support the extension of the classical neurohormonal scheme to a more comprehensive pathophysiological model that includes multiple hormonal and metabolic deficiencies. This chapter examines the evidence in support of this concept. Preliminary experience concerning targeted hormonal supplementation or metabolic modulation is also briefly reviewed in this article.

Original languageEnglish
Pages (from-to)57-69
Number of pages13
JournalFrontiers of Hormone Research
Volume43
DOIs
Publication statusPublished - 2014

Fingerprint

Heart Failure
Therapeutics
Health Expenditures
Thyroid Hormones
Developed Countries
Androgens
Growth Hormone
Quality of Life
Insulin
Cytokines
Delivery of Health Care
Survival
Mortality
Research

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Hormonal alterations in heart failure : Anabolic impairment in chronic heart failure - Diagnostic, prognostic and therapeutic issues. / Arcopinto, Michele; Cittadini, Antonio.

In: Frontiers of Hormone Research, Vol. 43, 2014, p. 57-69.

Research output: Contribution to journalArticle

@article{d1a7ff791f804faa9cdec1b1b0ed8c6f,
title = "Hormonal alterations in heart failure: Anabolic impairment in chronic heart failure - Diagnostic, prognostic and therapeutic issues",
abstract = "Chronic heart failure represents a leading cause of mortality and health care expenditure in developed countries. In the last 20 years, medical therapy of heart failure has dramatically changed thanks to the introduction of agents able to significantly reduce the neurohormonal hyperactivation that underpins the syndrome, and to the growing opportunities of electrical therapies. Although major advances in terms of improved survival and quality of life have been achieved, the reduction in the burden of heart failure is still the primary goal of cardiovascular societies. In the last decades, other research lines have also grown to complement the neurohormonal paradigm. It is increasingly evident that several hormonal systems are down-regulated or impaired in patients with heart failure, including growth and thyroid hormones, androgens and insulin. These abnormalities could be considered interrelated and linked, in turn, to the neurohormonal and cytokine hyperactivation. Since most of these alterations provide prognostic information, these new lines of evidence support the extension of the classical neurohormonal scheme to a more comprehensive pathophysiological model that includes multiple hormonal and metabolic deficiencies. This chapter examines the evidence in support of this concept. Preliminary experience concerning targeted hormonal supplementation or metabolic modulation is also briefly reviewed in this article.",
author = "Michele Arcopinto and Antonio Cittadini",
year = "2014",
doi = "10.1159/000360559",
language = "English",
volume = "43",
pages = "57--69",
journal = "Frontiers of Hormone Research",
issn = "0301-3073",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Hormonal alterations in heart failure

T2 - Anabolic impairment in chronic heart failure - Diagnostic, prognostic and therapeutic issues

AU - Arcopinto, Michele

AU - Cittadini, Antonio

PY - 2014

Y1 - 2014

N2 - Chronic heart failure represents a leading cause of mortality and health care expenditure in developed countries. In the last 20 years, medical therapy of heart failure has dramatically changed thanks to the introduction of agents able to significantly reduce the neurohormonal hyperactivation that underpins the syndrome, and to the growing opportunities of electrical therapies. Although major advances in terms of improved survival and quality of life have been achieved, the reduction in the burden of heart failure is still the primary goal of cardiovascular societies. In the last decades, other research lines have also grown to complement the neurohormonal paradigm. It is increasingly evident that several hormonal systems are down-regulated or impaired in patients with heart failure, including growth and thyroid hormones, androgens and insulin. These abnormalities could be considered interrelated and linked, in turn, to the neurohormonal and cytokine hyperactivation. Since most of these alterations provide prognostic information, these new lines of evidence support the extension of the classical neurohormonal scheme to a more comprehensive pathophysiological model that includes multiple hormonal and metabolic deficiencies. This chapter examines the evidence in support of this concept. Preliminary experience concerning targeted hormonal supplementation or metabolic modulation is also briefly reviewed in this article.

AB - Chronic heart failure represents a leading cause of mortality and health care expenditure in developed countries. In the last 20 years, medical therapy of heart failure has dramatically changed thanks to the introduction of agents able to significantly reduce the neurohormonal hyperactivation that underpins the syndrome, and to the growing opportunities of electrical therapies. Although major advances in terms of improved survival and quality of life have been achieved, the reduction in the burden of heart failure is still the primary goal of cardiovascular societies. In the last decades, other research lines have also grown to complement the neurohormonal paradigm. It is increasingly evident that several hormonal systems are down-regulated or impaired in patients with heart failure, including growth and thyroid hormones, androgens and insulin. These abnormalities could be considered interrelated and linked, in turn, to the neurohormonal and cytokine hyperactivation. Since most of these alterations provide prognostic information, these new lines of evidence support the extension of the classical neurohormonal scheme to a more comprehensive pathophysiological model that includes multiple hormonal and metabolic deficiencies. This chapter examines the evidence in support of this concept. Preliminary experience concerning targeted hormonal supplementation or metabolic modulation is also briefly reviewed in this article.

UR - http://www.scopus.com/inward/record.url?scp=84923589286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923589286&partnerID=8YFLogxK

U2 - 10.1159/000360559

DO - 10.1159/000360559

M3 - Article

C2 - 24943298

AN - SCOPUS:84923589286

VL - 43

SP - 57

EP - 69

JO - Frontiers of Hormone Research

JF - Frontiers of Hormone Research

SN - 0301-3073

ER -